Actively Recruiting
Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)
Led by Cancer Trials Ireland · Updated on 2026-02-20
1600
Participants Needed
3
Research Sites
267 weeks
Total Duration
On this page
Sponsors
C
Cancer Trials Ireland
Lead Sponsor
R
Royal College of Surgeons, Ireland
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to provide information about the genomics of your breast cancer which your oncologist can use to enhance the treatment of your disease possibly enabling more targeted and personalised therapy.This study will carry out TruSight Oncology Comprehensive (TSOComprehensive) testing on breast cancer tumour tissue that was collected at the time of your breast cancer diagnosis or during your breast surgery or if you have brain metastasis and you have had a biopsy for this. The TruSight Oncology Comprehensive assay is a next-generation sequencing (NGS) test used to analyse cancer-related genomic changes in patients, offering a comprehensive view of potential mutations and other alterations that can impact treatment decisions. The TruSight Oncology Comprehensive assay is CE-IVD marked for use in Europe, meaning that it complies with the relevant EU regulation, for comprehensive genomic profiling for different types of cancer. It analyses 523 cancer-relevant genes from both DNA and RNA to identify variations. It will also look for changes and mutations which may affect cell growth and stability. By identifying relevant mutations and biomarkers, the assay can help oncologists select the most appropriate treatment strategies with the aim of improving patient outcomes.
CONDITIONS
Official Title
Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with primary breast cancer attending hospital for tumor tissue resection
- Patients with suspected or confirmed brain metastatic breast cancer with history of biopsy or confirmed primary breast cancer, attending hospital for tumor tissue resection/biopsy or treatment
- Patients with suspected newly diagnosed brain metastatic breast cancer attending hospital for tumor tissue resection/biopsy or treatment
- Patients receiving neoadjuvant treatment are eligible
- Patients 18 years of age or older
- Patients able to give informed consent
You will not qualify if you...
- Patients without a confirmed diagnosis of primary breast cancer
- Patients considered by the principal investigator to be unsuitable for the study due to poor health or infirmity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Beaumont RCSI Cancer Centre
Dublin, Leinster, Ireland, D09V2N0
Actively Recruiting
2
Cork University Hospital
Cork, Ireland
Not Yet Recruiting
3
University Hospital Galway
Galway, Ireland
Not Yet Recruiting
Research Team
C
Cancer Trials Ireland
CONTACT
L
Leonie Young
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here